Diagnoses DiseaseNCT04788966
Evaluation of an Innovative Speech-enabled Translator in Emergency Settings
An observational study of Diagnoses Disease, run by University Hospital, Geneva at 1 site in Switzerland.
Trial summary
Survey-based satisfaction, performance and technical features evaluation of a speech-enabled fixed-phrase translation tool (BabelDR) in an emergency department. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Diagnoses Disease
- What is being tested?
- the translation tool BabelDr
- Type of treatment
- Medical device
- How many people
- 42 participants
- Where
- 1 siteSwitzerland
- Study dates
- 29 Nov 2018to 20 Jan 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: 30 patients were recruited with an average age of M=38.2 (SD=16.49) of which 53.33% were males. The distribution between the different languages was the following: Spanish (11), Arabic (4), Farsi (7), Tigrinya (7) and Albanian (1).
Who may be able to join
- As per inclusion criteria, patients were required to have no understanding of French, thus making a diagnostic interview by the doctors impossible.
Who cannot join
- Exclusion criteria concerned patients who shared a common language with the doctor and/or were not able to read in their native language.
Trial locations and contacts
1 site in 1 country.
About this study
Survey-based satisfaction, performance and technical features evaluation of a speech-enabled fixed-phrase translation tool (BabelDR) in an emergency department.
- Conditions
- Diagnoses Disease
- Being tested
- the translation tool BabelDr
- Keywords
- Translation tool, Anamnesis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
the translation tool BabelDrDevice
Doctors use a speech-enabled fixed-phrase translation tool to help communicate with an allophone patient.
What is being measured
The primary outcome is the main question the study is designed to answer.
Satisfaction evaluation through a 4-point scale survey
Are patients' and doctors' satisfied with the use of BabelDr?
Measured: During the consultation
Efficacy evaluation through a 2-point scale survey
Can BabelDr be efficient tool in an emergency context: are doctors' able to reach a diagnostic with the tool?
Measured: During the consultation
Technical features evaluation through a 4-point scale survey
Are the technical features appreciated by the doctors'?
Measured: During the consultation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Mar 2021
- Study start29 Nov 2018
- Primary completion20 Jan 2020
- Study completion20 Jan 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diagnoses DiseaseStudies of the same condition, open and under way.
- More trials run by University Hospital, GenevaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Other
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Geneva
- Sponsor type
- University, hospital or other
- Collaborators
- University of Geneva, Switzerland
- Responsible party
- Principal investigator, Antony Janakiram, University Hospital, Geneva
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04788966
- Sponsor's protocol ID
- Réq 2017-00996
- Status last verified
- Mar 2021
- First submitted
- 19 Feb 2021
- Last updated
- 9 Mar 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of an Innovative Speech-enabled Translator in Emergency Settings
- ClinicalTrials.gov ID
- NCT04788966
- Acronym / sponsor ID
- Réq 2017-00996
- Conditions
- Diagnoses Disease
- Keywords
- Translation tool, Anamnesis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- University Hospital, GenevaUniversity, hospital or other
- Collaborators
- University of Geneva, Switzerland
- Study start
- 29 Nov 2018 (actual)
- Primary completion
- 20 Jan 2020 (actual)
- Study completion
- 20 Jan 2020 (actual)
- First posted
- 9 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Survey-based satisfaction, performance and technical features evaluation of a speech-enabled fixed-phrase translation tool (BabelDR) in an emergency department.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Other
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- 30 patients were recruited with an average age of M=38.2 (SD=16.49) of which 53.33% were males. The distribution between the different languages was the following: Spanish (11), Arabic (4), Farsi (7), Tigrinya (7) and Albanian (1).
Key inclusion criteria (1 listed)
- As per inclusion criteria, patients were required to have no understanding of French, thus making a diagnostic interview by the doctors impossible.
Key exclusion criteria (1 listed)
- Exclusion criteria concerned patients who shared a common language with the doctor and/or were not able to read in their native language.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| the translation tool BabelDrDoctors use a speech-enabled fixed-phrase translation tool to help communicate with an allophone patient. | Device | – |
Primary outcome
Satisfaction evaluation through a 4-point scale survey
Time frame: During the consultation
Are patients' and doctors' satisfied with the use of BabelDr?
Efficacy evaluation through a 2-point scale survey
Time frame: During the consultation
Can BabelDr be efficient tool in an emergency context: are doctors' able to reach a diagnostic with the tool?
Technical features evaluation through a 4-point scale survey
Time frame: During the consultation
Are the technical features appreciated by the doctors'?
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Diagnoses Disease
Enrolling by invitationObservational study
Radiomics-Based Non-Invasive MRI Differentiation of Uterine Sarcomas and Fibroids
Uterine Fibroid, Uterine Sarcoma
Recruiting
Optimizing Bronchopulmonary Cancer Screening
Bronchopulmonary Disease, Diagnoses Disease
Recruiting
HEARTBEAT-TROP. Polyethylene Glycol Precipitation to Unmask Macrotroponin
Diagnoses Disease
Active, not recruitingObservational study
Socioeconomic Inequalities in the Diagnosis and Treatment of Colon and Ovarian Cancer in England Between 2016-2017
Treatment Related Cancer, Diagnoses Disease
RecruitingObservational study
Artificial Intelligence for Highly Myopic Cataract
Cataract, High Myopia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diagnoses Disease, run by University Hospital, Geneva at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Satisfaction evaluation through a 4-point scale survey (time frame: During the consultation). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2021; AzTrials last refreshed its copy on 6 Nov 2026.